Kyoko Fujiwara

Kyoko Fujiwara

Auto-generated profile, based on publicly available information

Kyoko Fujiwara

Department of Anatomy, Nihon University School of Dentistry, Chiyoda-ku, Tokyo 101-8310, Japan; Division of Functional Morphology, Dental Research Center, Nihon University School of Dentistry, Chiyoda-ku, Tokyo 101-8310, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
KSKosuke Saito
Kosuke Saito
TATomohiko Asai
Tomohiko Asai
KFKyoko Fujiwara
Kyoko Fujiwara
JSJunki Sahara
Junki Sahara
HKHaruhisa Koguchi
Haruhisa Koguchi
YSYoshihiro Suzuki-Karasaki
Yoshihiro Suzuki-Karasaki
Tumor-selective mitochondrial network collapse induced by atmospheric gas plasma-activated medium

1 January 2014 in FEBS Open Bio
Verified
Journal Article
Open access
MTMasashi Taniguchi
Masashi Taniguchi
KFKyoko Fujiwara
Kyoko Fujiwara
YNYuji Nakai
Yuji Nakai
TOToshinori Ozaki
Toshinori Ozaki
NKNobuko Koshikawa
Nobuko Koshikawa
HNHiroki Nagase
Hiroki Nagase
Gene amplification and/or overexpression of the transcription factor c‐MYC, which binds to the E‐box sequence (5′‐CACGTG‐3′), has been observed in many human tumors. In this study, we have designed 5 pyrrole–imidazole (PI) polyamides recognizing E‐box, and found that, among them, Myc‐6 significantly suppresses malignant phenotypes of human osteosarcoma MG63 cells both in vitro and in vivo. Intriguingly, knockdown of the putative Myc‐6 target MALAT1 encoding long noncoding RNA remarkably impaired cell growth of MG63 cells. Collectively, our present findings strongly suggest that Myc‐6 exerts its tumor‐suppressive ability at least in part through the specific down‐regulation of MALAT1.

24 February 2017 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
RHReina Hoshi
Reina Hoshi
YWYosuke Watanabe
Yosuke Watanabe
YIYoshiaki Ishizuka
Yoshiaki Ishizuka
THTakayuki Hirano
Takayuki Hirano
ENEri Nagasaki-Maeoka
Eri Nagasaki-Maeoka
KFKyoko Fujiwara
Kyoko Fujiwara
Neuroblastoma is a childhood malignancy originating from the sympathetic nervous system and accounts for approximately 15% of all pediatric cancer-related deaths. To newly identify gene(s) implicated in the progression of neuroblastoma, we investigated aberrantly methylated genomic regions in mouse skin tumors. Previously, we reported that TFAP2E, a member of activator protein-2 transcription factor family, is highly methylated within its intron and its expression is strongly suppressed in mouse skin tumors compared with the normal skin. In the present study, we analyzed public data of neuroblastoma patients and found that lower expression levels of TFAP2E are significantly associated with a shorter survival. The data indicate that TFAP2E acts as a tumor suppressor of neuroblastoma. Consistent with this notion, TFAP2E-depleted neuroblastoma NB1 and NB9 cells displayed a substantial resistance to DNA damage arising from adriamycin (ADR), cisplatin (CDDP) and ionizing radiation (IR). Silencing of TFAP2E caused a reduced ADR-induced proteolytic cleavage of caspase-3 and PARP. Of note, compared with the untransfected control cells, ADR-mediated stimulation of CDK inhibitor p21WAF1 was markedly upregulated in TFAP2E‑knocked down cells. Therefore, our present findings strongly suggest that TFAP2E has a pivotal role in the regulation of DNA damage response in NB cells through the induction of p21WAF1.

7 August 2015 in Mammalian Genome
Verified
Journal Article
Closed access
PDF file
YOYumi Ozaki
Yumi Ozaki
KFKyoko Fujiwara
Kyoko Fujiwara
MIMaki Ikeda
Maki Ikeda
TOToshinori Ozaki
Toshinori Ozaki
TTTadashi Terui
Tadashi Terui
HNHiroki Nagase
Hiroki Nagase

10 April 2013 in SpringerPlus
Verified
Journal Article
Open access
PDF file
KTkeiko takagi
keiko takagi
KFKyoko Fujiwara
Kyoko Fujiwara
TTTadatoshi Takayama
Tadatoshi Takayama
TMTakao Mamiya
Takao Mamiya
MSMasayoshi Soma
Masayoshi Soma
HNHiroki Nagase
Hiroki Nagase
Background: Hepatocellular carcinoma (HCC) is one of the most common human malignancies in the world, and its prognosis is generally poor. Epigenetic alteration such as DNA methylation has been shown to be important in the development of human cancers including HCC. Here, we analyzed the methylation status of ZAR1, which has been reported to be aberrantly methylated in a few human cancers. Methods: We investigated the methylation status of ZAR1 in 88 HCV-positive HCC and matched nontumorous liver tissue samples and 4 normal liver tissue samples used as a control using MassARRAY EpiTYPER. Further statistical analysis was performed to determine the relationship between methylation level and patient clinicopathological features and prognosis. Results: CpG islands in ZAR1 exon 1 showed a higher methylation level in all 88 HCC than in nontumorous tissues. The hypermethylation group, whose cancer tissues showed a twofold or higher methylation level compared with nontumorous tissues, showed a significantly higher serum AFP (p = 0.018) and lower serum albumin (p = 0.001) and single rather than multiple tumors (p = 0.031) compared with the hypomethylation group. Multivariate regression analyses were performed to identify which of the following factors were the predictors of the hypermethylation group: serum albumin, AFP, and tumor multiplicity. This study showed that patients who had Zar1 hypermethylation in the HCC tissues had a significantly lower serum albumin level than those in the hypomethylation group (p = 0.007). Conclusion: Although it is still unknown how ZAR1 hypermethylation affects HCC development, it could be a potential marker to detect HCV-related HCC.

1 April 2013 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
KSKiminobu Sugito
Kiminobu Sugito
HKHiroyuki Kawashima
Hiroyuki Kawashima
SYShinsuke Yoshizawa
Shinsuke Yoshizawa
SUShota Uekusa
Shota Uekusa
RHReina Hoshi
Reina Hoshi
HNHiroki Nagase
Hiroki Nagase